James William Rogers Sells 83,025 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 83,025 shares of Tempus AI stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.30, for a total transaction of $3,511,957.50. Following the completion of the transaction, the chief financial officer now owns 231,280 shares in the company, valued at $9,783,144. This trade represents a 26.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Tempus AI Trading Down 2.4 %

TEM stock traded down $0.99 during midday trading on Friday, reaching $41.00. 5,041,241 shares of the company’s stock traded hands, compared to its average volume of 1,427,998. The business has a 50-day moving average of $52.88. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $79.49.

Institutional Trading of Tempus AI

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. EFG Asset Management North America Corp. bought a new stake in Tempus AI during the 2nd quarter worth about $1,333,000. ARK Investment Management LLC bought a new stake in shares of Tempus AI during the second quarter valued at approximately $18,294,000. Northwestern University acquired a new stake in shares of Tempus AI in the second quarter valued at approximately $491,000. Alphabet Inc. acquired a new stake in shares of Tempus AI in the second quarter valued at approximately $54,289,000. Finally, Pier Capital LLC bought a new position in Tempus AI in the 2nd quarter worth approximately $2,301,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on TEM shares. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and raised their price objective for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Bank of America boosted their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Friday. They issued an “outperform” rating and a $60.00 target price for the company. Piper Sandler restated a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, Guggenheim began coverage on Tempus AI in a research report on Monday. They issued a “buy” rating and a $74.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.